Treatment of parkinsonism with bromocriptine
DB Calne, PN Leigh, PF Teychenne, AN Bamji… - The Lancet, 1974 - Elsevier
Bromocriptine, a drug which acts directly upon dopaminergic receptors, has been
administered to parkinsonian patients. The dose of bromocriptine was built up, while
simultaneously levodopa was reduced or even stopped. Bromocriptine was found to have a
potent therapeutic action, quite comparable to that of levodopa. Adverse reactions
resembled those induced by levodopa.
administered to parkinsonian patients. The dose of bromocriptine was built up, while
simultaneously levodopa was reduced or even stopped. Bromocriptine was found to have a
potent therapeutic action, quite comparable to that of levodopa. Adverse reactions
resembled those induced by levodopa.
Long-term treatment of parkinsonism with bromocriptine
DB Calne, AC Williams, A Neophytides, C Plotkin… - The Lancet, 1978 - Elsevier
Abstract 92 patients with parkinsonism have been treated with bromocriptine for up to 30
months. 48 continue to receive bromocriptine with benefit; of these, 35 take bromocriptine
(mean dose 53 mg daily) in combination with levodopa and 13 take bromocriptine (mean
dose 45 mg daily) without levodopa. In those who were originally on levodopa, addition of
bromocriptine allowed a mean 41% reduction in the dose of levodopa; the largest group of
patients to benefit from bromocriptine entered the study because of excessive dyskinesia or" …
months. 48 continue to receive bromocriptine with benefit; of these, 35 take bromocriptine
(mean dose 53 mg daily) in combination with levodopa and 13 take bromocriptine (mean
dose 45 mg daily) without levodopa. In those who were originally on levodopa, addition of
bromocriptine allowed a mean 41% reduction in the dose of levodopa; the largest group of
patients to benefit from bromocriptine entered the study because of excessive dyskinesia or" …
